Lore IO Announces COVID-19 Data Onboarding Initiative

By on

A new press release reports, “Lore IO Inc., providers of an AI-powered common data model that enables unified data views and faster vendor onboarding, today announced the availability of its COVID-19 Data Onboarding Initiative, a program designed to help pharmaceutical organizations shorten development cycles to speed drug readiness. The program, which is free of charge to pharma and biopharma manufacturers, allows organizations to onboard data from up to three unique sources in only 30 days instead of months which is the time it typically takes using traditional methods. For more information, and to sign up for the no-cost trial, visit www.getlore.io/covid-19-data-onboarding-initiative.”

The release goes on, “Lore IO’s COVID-19 Data Onboarding Initiative will help established and emerging biopharma companies further accelerate the development and operationalization of enterprise data warehouses and commercialized analytics during pre-drug launch phases. The program focuses on expediting the onboarding and transformation of three vendor sources of industry data, which allows the user to create a unified view of the data for analysis and accelerate the execution of their go-to-market plan. ‘I can personally attest to how our company was able to deliver a minimum viable product of a commercial app in just 30 days using Lore IO’s solution,’ said Todd Dekkinga, Head of IT at pharmaceutical company Oncopeptides. ‘The ability to rapidly onboard data was a real game changer, as it will enable us with the speed and agility needed for our upcoming drug, Melflufen, first-in-class, anti-cancer peptide drug for multiple myeloma patients’.”

Read more at PR Newswire.

Image used under license from Shutterstock.com

We use technologies such as cookies to understand how you use our site and to provide a better user experience. This includes personalizing content, using analytics and improving site operations. We may share your information about your use of our site with third parties in accordance with our Privacy Policy. You can change your cookie settings as described here at any time, but parts of our site may not function correctly without them. By continuing to use our site, you agree that we can save cookies on your device, unless you have disabled cookies.
I Accept